Avel eCare

Avel eCare

Avel eCare began in 1993 as a grant-funded telehealth pilot at what was then Sioux Valley Hospital, with the goal of bringing specialist coverage to rural emergency rooms across South Dakota. The unit evolved into a self-sustaining entity that provides 24/7 virtual care across emergency medicine, critical care, pharmacy, school health, and behavioral health. Foundational wealth-origin details are not publicly disclosed; administrative records trace the entity's roots to the Avera Health system, a Catholic-sponsored integrated delivery network that serves the Upper Midwest. The organization operates an on-demand telemedicine platform delivering clinical services rather than a portfolio of financial assets. Core lines of business include emergency telemedicine, eICU monitoring, telepharmacy services, and direct-to-consumer urgent care. Service contracts cover over 650 hospitals, clinics, long-term care facilities, and schools across more than 30 states. This is an operating business that generates revenue through service agreements and subscription models — not an investment firm allocating to third-party managers. No AUM or professional-investment headcount applies. Avel eCare does not deploy capital, manage a portfolio of companies, or maintain a fund structure. It employs clinical and operational staff to deliver virtual care. In the last 24 months, the organization has expanded its school-based telehealth and behavioral health programs in response to growing demand in rural school districts (public record). Avera Health, the sponsoring system, operates a philanthropic foundation that supports community health initiatives but does not represent an adjacent investment vehicle in the family-office sense. Avel eCare's structural distinction is its identity as a clinical service line rather than a family office or asset manager. It represents the kind of operating asset a family office might own — a vertically integrated telehealth provider embedded within a larger health system — but it does not manage wealth, evaluate GPs, or invest in external funds. Reviewers encountering this profile in an allocation context should reclassify it as a potential portfolio company or co-investment target, not as an allocator.